Helsinki-based nanoparticle medicine specialist Nanoform has completed a new share issue, in the process raising about €25 million from global and Nordic institutional investors. This will mainly be used to build a GMP manufacturing site in the US, where most of the company’s customers are.

CDMO and API manufacturer Seqens has announced a “multi-million dollar” investment in its R&D laboratory in Devens, Massachusetts, which is due to be completed in October. The firm said that this will ensure that the new facility can operate at the highest standards of safety and quality.

CDMO Flamma has acquired a third API manufacturing facility in Italy from Teva. The Sicor Bulciago site at Lecco has had multiple regulatory inspections. Terms were not disclosed.

“This allows us to rapidly enhance our CMC offerings to our customers by providing further flexibility between sites,” said CEO Dr Gianpaolo Negrisoli. “Having the ability to produce more generic APIs in Italy is in line with the European pharmaceutical strategy aiming to reshore.”

Spectrum Chemical has added 12 new products to its BioCertified quality management system and chemicals portfolio for biopharmaceutical manufacturing, which was originally launched in 2019. They include sugars and carbohydrates, organic and inorganic salts, and preservatives used in a wide range of bioprocessing applications from upstream cell culture development to downstream purification, polishing and final fill production.

Drug development firm CatSci has secured £4.5 million of investment from ‘alternative lender’ Boost & Co. This is described as a continuation of the Cardiff-based firm’s £3 million investment, which was started in 2021.

CatSci will use the funding to install new equipment and expand its laboratories by adding capabilities in chemical and analytical development, material science, product formulation and GMP analytical testing in both Cardiff and London. Some will be used to refinance its existing debt.

Lonza has completed an expansion at its API manufacturing site at Nansha, China, as part of its recent investment to expand mid-scale capacity there. This focused on extending the capabilities and capacity of development laboratories and kilo-scale cGMP manufacturing laboratories for clinical supply of HPAPIs.

Sinocompound Catalysts, a supplier of advanced homogeneous catalysts and ligands based in Zhangjiagang, China, has announced production of QPhos in kilogram quantities. Hitherto, the company said, its use in process development and scale-up has been hindered by the lack of commercial-scale capacity, despite its huge potential.